Meeting NewsVideo

VIDEO: Anabasum shows acceptable safety, tolerability for diffuse system sclerosis

SAN DIEGO — At the American College of Rheumatology Annual Meeting, Robert F. Spiera, MD, of the Hospital for Special Surgery, spoke about the safety and efficacy of anabasum, a cannabinoid receptor type 2 agonist, for the treatment of diffuse systemic sclerosis.

Spiera said in this phase 2 study of 42 patients, anabasum had acceptable safety in diffuse systemic sclerosis with evidence of clinical benefit. Additionally, there were a strong correlation in the ACR Combined Response Index in Diffuse Cutaneous System Sclerosis scores, which was the primary efficacy outcome.

SAN DIEGO — At the American College of Rheumatology Annual Meeting, Robert F. Spiera, MD, of the Hospital for Special Surgery, spoke about the safety and efficacy of anabasum, a cannabinoid receptor type 2 agonist, for the treatment of diffuse systemic sclerosis.

Spiera said in this phase 2 study of 42 patients, anabasum had acceptable safety in diffuse systemic sclerosis with evidence of clinical benefit. Additionally, there were a strong correlation in the ACR Combined Response Index in Diffuse Cutaneous System Sclerosis scores, which was the primary efficacy outcome.

    See more from American College of Rheumatology Annual Meeting